Sinovac Biotech Ltd. (NASDAQ:SVA) raised $57.5 million through the sale of 10 million shares at $5.75 in a bumped-up follow-on underwritten by UBS and Piper Jaffray. Sinovac proposed to sell 8.7 million shares last week,...

Sinovac Biotech Ltd. (NASDAQ:SVA) proposed late Wednesday to sell 8.7 million shares in a follow-on underwritten by UBS and Piper Jaffray. If sold at Sinovac's Wednesday close of $7.51, the company would raise $65 million....

SVA launched its Bilive vaccine to prevent hepatitis A and B infection in China. Sinovac Biotech Ltd. (SVA), Beijing, China   Business: Infectious  ...

SVA received Chinese marketing and sales approval for Bilive, a combined hepatitis A & B vaccine. Sinovac Biotech Ltd. (SVA), Beijing, China   Product: Bilive   Business: Infectious  ...